Within the US alone, there are over 200,000 hospitalizations annually from seasonal viral influenza. Patients requiring mechanical ventilation have a high mortality rate of 20% or over 40,000 people annually.

The World Health Organization (WHO) estimates that influenza impacts between 3 Million and 5 Million people worldwide causing between 250,000 and 500,000 deaths annually from respiratory distress and failure. These deaths do not include other respiratory diseases such as adenovirus, rhinovirus, hMPV, PIV, RSV etc.

NDC-1308 (MC1) has a known MOA that directly shifts pro-inflammatory M1 macrophages to the anti-inflammatory M2 state, and is agnostic to the type of virus infecting and inflaming the lungs. Therefore, there is a strong need for NDC-1308 (MC1) to treat lung inflammation beyond SARS-CoV-2, COVID-19, and future Coronaviruses. NDC-1308 (MC1) will be an important treatment for all viral respiratory diseases, preventing progression to respiratory distress, respiratory failure, and death.